Kowa Research Institute, Inc.

The Corneal Endothelial Dystrophy market is growing, driven by increased prevalence, R&D investments, and new therapies like Sirolimus and TTHX1114. With 18 million cases in 2023, the market expects an 8% CAGR from 2024-2034. Current treatments are limited, highlighting the need for non-invasive, FDA-approved drugs and advancements in endothelial regeneration.

Clinipace, Inc., founded in 2003 in Morrisville, NC, offers digital contract research solutions for life science firms, focusing on regulatory strategies, clinical development, and post-approval research. Kowa Research Institute, Inc., also in Morrisville, specializes in the clinical development of new drugs for Kowa Company.

Clinipace, Inc., founded in 2003 in Morrisville, NC, offers digital contract research solutions for life science firms, including clinical monitoring and data management. Kowa Research Institute, Inc., also in Morrisville, focuses on clinical development of new drugs for Kowa Company.